Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Mol Graph Model ; 123: 108503, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37209440

RESUMO

The single-point mutation D26E in human ß-tubulin is associated with drug resistance seen with two anti-mitotic taxanes (paclitaxel and docetaxel) when used to treat cancers. The molecular mechanism of this resistance remains elusive. However, docetaxel and a third-generation taxane, cabazitaxel, are thought to overcome this resistance. Here, structural models of both the wildtype (WT) and D26E mutant (MT) human ß-tubulin were constructed based on the crystal structure of pig ß-tubulin in complex with docetaxel (PDB ID: 1TUB). The three taxanes were docked into the WT and MT ß-tubulin, and the resulting complexes were submitted to three independent runs of 200 ns molecular dynamic simulations, which were then averaged. MM/GBSA calculations revealed the binding energy of paclitaxel with WT and MT ß-Tubulin to be -101.5 ± 8.4 and -90.4 ± 8.9 kcal/mol, respectively. The binding energy of docetaxel was estimated to be -104.7 ± 7.0 kcal/mol with the WT and -103.8 ± 5.5 kcal/mol with the MT ß-tubulin. Interestingly, cabazitaxel was found to have a binding energy of -122.8 ± 10.8 kcal/mol against the WT and -106.2 ± 7.0 kcal/mol against the MT ß-tubulin. These results show that paclitaxel and docetaxel bound to the MT less strongly than the WT, suggesting possible drug resistance. Similarly, cabazitaxel displayed a greater binding propensity against WT and MT ß-tubulin than the other two taxanes. Furthermore, the dynamic cross-correlation matrices (DCCM) analysis suggests that the single-point mutation D26E induces a subtle dynamical difference in the ligand-binding domain. Overall, the present study revealed how the single-point mutation D26E may reduce the binding affinity of the taxanes, however, the effect of the mutation does not significantly affect the binding of cabazitaxel.


Assuntos
Resistencia a Medicamentos Antineoplásicos , Tubulina (Proteína) , Humanos , Animais , Suínos , Tubulina (Proteína)/química , Docetaxel/farmacologia , Taxoides/farmacologia , Taxoides/química , Paclitaxel/farmacologia , Paclitaxel/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA